Am I a Candidate? Contact

Regenerative Wellness, Redefined

Bangkok, Thailand

World map showing different regulatory frameworks by region
CLINICAL EVIDENCE

Regulatory Landscape: FDA, EMA, and International Standards

Overview of global stem cell regulations including FDA (21 CFR Part 1271), EMA guidelines, and international standards. Essential reading for understanding treatment options.

Medical Content Team Content Team
April 10, 2026 · 10 min read

Key Takeaways

  • Stem cell therapy is regulated differently across jurisdictions
  • FDA classifies many stem cell products as drugs requiring approval
  • Thailand has established regulatory framework for regenerative medicine
  • International standards (ISO, GMP) ensure quality regardless of location
  • People considering treatment should understand the regulatory status of their therapy

Why Regulation Matters

Guest Safety

Regulations exist to:

  • Ensure product quality and consistency
  • Minimize contamination risks
  • Verify clinical evidence
  • Protect people from unproven treatments

Industry Credibility

Proper regulation:

  • Separates legitimate clinics from "stem cell tourism"
  • Establishes standards of care
  • Enables insurance coverage (eventually)
  • Supports research advancement

United States: FDA Regulation

Current Framework

21 CFR Part 1271

The FDA regulates human cells and tissues under this rule (FDA, 2024):

HCT/Ps (Human Cells, Tissues, and Cellular and Tissue-Based Products)

Two Pathways:

1. 361 Pathway (Minimally Manipulated)

  • Same-day procedures
  • Autologous (your own cells)
  • No culture expansion
  • Homologous use only
  • Examples: Bone marrow aspiration, adipose transfer

2. 351 Pathway (Drug Approval)

  • Culture-expanded cells
  • Allogeneic (donor cells)
  • Non-homologous use
  • Requires IND and clinical trials
  • Examples: Commercial stem cell products

FDA Enforcement

Recent Actions

The FDA has taken a more active enforcement posture in recent years (FDA, 2023; Turner and Knoepfler, 2016):

  • Warning letters to non-compliant clinics
  • Court actions against unsafe operators
  • Consumer education campaigns

What This Means

Most advanced stem cell therapies (cultured, allogeneic) cannot be legally offered in the US outside clinical trials (Li and Atkins, 2020).

Why People Travel

This regulatory environment leads US residents to seek treatment in jurisdictions with different frameworks (Lindvall and Hyun, 2009; Regenberg, 2017).

European Union: EMA Regulation

Advanced Therapy Medicinal Products (ATMP)

Classification

Stem cells are typically regulated under the EMA's ATMP framework (European Medicines Agency, 2024; Li and Atkins, 2020) as:

  • Somatic Cell Therapy Medicinal Products
  • Require Marketing Authorization

Approved Products

Limited approved stem cell therapies:

  • Holoclar (limbal stem cells for eye)
  • Alofisel (darvadstrocel for Crohn's fistulas)
  • Strimvelis (gene therapy)

Member State Variation

Some EU countries have more flexible frameworks:

  • Netherlands: Hospital exemption
  • Germany: Special access programs

Thailand: Thai FDA Regulation

Regulatory Framework

Thai FDA Authority

Thailand has established regulations for stem cell therapies (Thai Food and Drug Administration, 2024):

  • Cell processing facilities
  • Stem cell therapy clinics
  • Import/export of biological products

Licensing Requirements

Facilities must obtain:

  • Cell Processing License
  • Clinical Application License
  • Import License (if applicable)

Sterling-Certified Partner Compliance

Sterling-certified partner clinics in Thailand hold:

  • ✅ Thai FDA cell processing license
  • ✅ Clinical application authorization
  • ✅ ISO 9001:2015 certification
  • ✅ GMP-compliant laboratory

Thai Standards

Quality Requirements

  • Facility inspections
  • Documentation standards
  • Personnel qualifications
  • Environmental monitoring

Guest Protections

  • Informed consent requirements
  • Adverse event reporting
  • Record retention
  • International guest provisions

International Standards

ISO Certifications

ISO 9001:2015

Quality management systems (International Organization for Standardization, 2015)

Sterling-certified partner status: ✅ Certified

ISO 13485

Medical device quality management

Relevance: Laboratory equipment

ISO 17025

Testing laboratory competence

Relevance: Cell quality testing

Good Manufacturing Practice (GMP)

Principles

  • Documented procedures
  • Quality control at each step
  • Environmental monitoring
  • Personnel training
  • Equipment validation

Sterling-Certified Laboratory Standards

Sterling-certified partner laboratories follow:

  • GMP principles for cell processing
  • Clean room standards (ISO 7)
  • Batch testing and release
  • Full traceability

ISSCR Guidelines

International Society for Stem Cell Research

Publishes guidelines for clinical translation, research ethics, and communications with people considering treatment (International Society for Stem Cell Research, 2024; Master and Crozier, 2017).

Sterling Partner Adherence

Sterling-certified partner clinics follow ISSCR recommendations for:

  • Informed consent
  • Clinical evidence
  • Guest education
  • Marketing claims

Global Regulatory Trends

Harmonization Efforts

Organizations working toward global standards (World Health Organization, 2021; Rao and Mason, 2017):

  • WHO
  • International Council for Harmonisation (ICH)
  • Global Harmonization Task Force

Emerging Trends

The regulatory landscape continues to evolve as evidence accumulates (Levine, 2019).

1. Risk-Based Classification

Regulators moving toward risk-based frameworks:

  • Lower risk: Less stringent oversight
  • Higher risk: More rigorous requirements

2. Real-World Evidence

Growing acceptance of:

  • Registry data
  • Patient-reported outcomes
  • Long-term follow-up studies

3. Expedited Pathways

Some jurisdictions offering:

  • Conditional approvals
  • Expanded access programs
  • Fast-track designations

Understanding Regulatory Status

Questions to Ask Before Treatment

1. What is the regulatory status of this treatment?

  • Is it approved? Experimental? Part of a trial?

2. What licenses does the facility hold?

  • Cell processing? Clinical application?

3. Are there quality certifications?

  • ISO? GMP? National standards?

4. What protections exist for international guests?

  • Informed consent? Complaint mechanisms?

Red Flags

Unregulated Facilities:

People considering treatment should be aware of warning signs that may indicate unregulated or substandard operations (Sipp, 2011; Zarzeczny, Clark and Caulfield, 2020; Petersen and Seear, 2011):

  • No visible licenses
  • No quality certifications
  • "No questions asked" approach
  • Cash-only, no documentation

False Claims:

  • "FDA approved" (when not)
  • "Cure" claims
  • No mention of regulatory status

Legal Considerations for International Guests

US Residents Traveling Abroad

Legal to:

  • Travel for treatment
  • Receive treatment abroad
  • Pay for services

Cannot:

  • Import stem cell products for personal use
  • Market services in US without approval

Should:

  • Understand treatment is not FDA-approved
  • Ensure documentation for customs
  • Declare if asked

Medical Tourism Considerations

Insurance

Generally not covered:

  • Out-of-country treatment
  • Experimental therapies
  • May cover complications (check policy)

Malpractice/Legal Recourse

  • Different legal systems
  • May be limited recourse
  • Choose reputable facilities

The Sterling Partner Commitment to Compliance

Documentation

Sterling-certified partner clinics provide:

  • Certificate of Analysis for every treatment
  • Full treatment records
  • Informed consent documentation
  • Regulatory compliance certificates

Transparency

Sterling-certified partner clinics disclose:

  • Regulatory status of treatment
  • Licensing information
  • Quality certifications
  • Limitations and risks

Continuous Improvement

Sterling-certified partner clinics:

  • Monitor regulatory changes
  • Update protocols accordingly
  • Pursue additional certifications
  • Participate in industry standards development

Comparison by Jurisdiction

The Bottom Line

For You

Understand:

  • Regulatory status of your treatment
  • Quality standards of the facility
  • Your rights and protections
  • Limitations of legal recourse

For Sterling-Certified Partner Clinics

Sterling-certified partner clinics operate within:

  • Thai FDA regulations
  • International standards (ISO, GMP)
  • Professional guidelines (ISSCR)
  • Ethical principles

The Future

Regulatory landscape is evolving:

  • More approvals expected
  • Standards harmonizing
  • Access improving for those seeking treatment
  • Evidence base growing

Frequently Asked Questions

"Is stem cell therapy FDA-approved?"

Some products are. Most advanced therapies (cultured MSCs) are not FDA-approved but are legally available in other jurisdictions.

"Is it legal to get treatment in Thailand?"

Yes. Thai FDA regulates and licenses stem cell therapy. It's legal to travel there and receive treatment.

"What protections do I have?"

As an international guest in Thailand, you have:

  • Informed consent rights
  • Medical malpractice protections
  • Facility licensing requirements
  • Quality standards

"Can I bring cells back to the US?"

Generally no. FDA restricts import of biological products for personal use.

"Is your facility certified?"

Yes. Sterling-certified partner clinics hold Thai FDA licenses and ISO 9001:2015 certification.

Resources

Regulatory Bodies

  • FDA: fda.gov
  • EMA: ema.europa.eu
  • Thai FDA: fda.moph.go.th
  • ISSCR: isscr.org

Databases

  • ClinicalTrials.gov
  • EU Clinical Trials Register
  • WHO International Clinical Trials Registry

This content is for educational purposes only and does not constitute medical advice. Stem cell treatments are not FDA-approved for most conditions discussed. Individual results vary significantly. The regulatory status of these therapies differs by country. Always consult with a qualified healthcare provider before making treatment decisions.

References

  1. ↑ FDA (2024). Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. [Link] Tier 2
  2. ↑ FDA (2023). Enforcement Policy Regarding Human Cells, Tissues, and Cellular and Tissue-Based Products: Regulation and Registration. , 88 , pp. 3456-3468 Tier 2
  3. ↑ European Medicines Agency (2024). Advanced Therapy Medicinal Products: Overview. [Link] Tier 2
  4. ↑ Thai Food and Drug Administration (2024). Regulation of Stem Cell and Cell Therapy Products in Thailand. Tier 1
  5. ↑ International Society for Stem Cell Research (2024). Guidelines for Stem Cell Research and Clinical Translation. [Link] Tier 2
  6. ↑ International Organization for Standardization (2015). ISO 9001:2015 Quality management systems — Requirements. Tier 1
  7. ↑ World Health Organization (2021). Global Benchmarking Tool for Evaluation of National Regulatory Systems of Medical Products. Tier 1
  8. ↑ Turner, L. and Knoepfler, P. (2016). Selling stem cells in the USA: assessing the direct-to-consumer industry. , 19 , pp. 154-157 doi:10.1016/j.stem.2016.06.007 Tier 1
  9. ↑ Lindvall, O. and Hyun, I. (2009). Medical innovation versus stem cell tourism. , 324 , pp. 1664-1665 doi:10.1126/science.1171749 Tier 1
  10. ↑ Rao, M. and Mason, C. (2017). Regenerative medicine: do the costs of regulation outweigh the benefits?. , 20 , pp. 577-579 doi:10.1016/j.stem.2017.04.012 Tier 1
  11. ↑ Li, M.D. and Atkins, H. (2020). Regulatory pathways for advanced therapy medicinal products in the United States, European Union, and Japan. , 15 , pp. 1741-1758 doi:10.2217/rme-2020-0034 Tier 1
  12. ↑ Zarzeczny, A., Clark, K. and Caulfield, T. (2020). Stem cell tourism: the tensions and challenges of communicating health information to the public. , 22 , pp. 184-191 doi:10.1016/j.jcyt.2020.02.002 Tier 1
  13. ↑ Petersen, A. and Seear, K. (2011). Technologies of hope: techniques of the online advertising of stem cell treatments. , 30 , pp. 329-346 doi:10.1080/14636778.2011.592984 Tier 1
  14. ↑ Sipp, D. (2011). The unregulated commercialization of stem cell treatments: a global perspective. , 3 , pp. 94 doi:10.3389/fcell.2015.00094 Tier 1
  15. ↑ Master, Z. and Crozier, G.K. (2017). Policy, ethics, and oversight of international clinical stem cell research. , 45 , pp. 332-343 doi:10.1177/1073110517737276 Tier 1
  16. ↑ Regenberg, A. (2017). The advent of international stem cell tourism: what can we learn from traditional models of medical tourism?. , 19 , pp. 1423-1429 doi:10.1016/j.jcyt.2017.09.005 Tier 1
  17. ↑ Levine, A.D. (2019). The evolution of the stem cell landscape: navigating regulatory and commercial challenges. , 37 , pp. 342-345 doi:10.1038/s41587-019-0073-2 Tier 1

Ready to Learn More?

Discover if regenerative medicine is right for you.

Take Free Assessment